Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 8/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958790 | 0.85 | MAPK14 (0.51) | CDK8 | |
| SCHEMBL1049986 | 0.84 | CYP2C19 (0.49) | CYP2C19HTR6PKMCCNE1CDK2 | |
| SCHEMBL970398 | 0.79 | CDC7 (0.39) | HTR6CCNE1CDK2 | |
| SCHEMBL970112 | 0.78 | HTR6 (0.38) | HTR6CDK2CDK8 | |
| SCHEMBL1044724 | 0.78 | CDK2 (0.47) | CYP2C19HTR6PKMCCNE1CDK2 | |
| SCHEMBL1051384 | 0.74 | HTR6 (0.46) | HTR6ELAVL1BRD4 | |
| SCHEMBL29604761 | 0.74 | CYP2C19 (0.42) | CYP2C19HTR6CCNE1CDK2MET | |
| SCHEMBL13306694 | 0.73 | CYP2C19 (0.49) | CYP2C19HTR6PKMCCNE1CDK2 | |
| SCHEMBL956933 | 0.73 | CYP2C19 (0.49) | CYP2C19HTR6PKMCCNE1CDK2 | |
| SCHEMBL1049755 | 0.73 | CCNC (0.46) | CYP2C19HTR6PKMCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454262-B1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LAB (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8383624-B2 | Pyrrolopyrazine inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | CYP2C19 3532/4885HTR6 4700/4885PKM 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.